NovoCure Limited
NVCR
$11.13
-$0.55-4.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.17% | 14.58% | 18.27% | 18.82% | 14.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.17% | 14.58% | 18.27% | 18.82% | 14.63% |
| Cost of Revenue | 16.02% | 11.82% | 7.18% | 6.82% | 9.29% |
| Gross Profit | 9.68% | 15.46% | 21.98% | 22.84% | 16.38% |
| SG&A Expenses | 16.21% | 15.05% | 11.87% | 10.83% | 1.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.07% | 10.12% | 7.44% | 5.34% | 0.33% |
| Operating Income | -15.48% | 3.66% | 20.03% | 25.03% | 31.91% |
| Income Before Tax | -31.45% | -0.66% | 24.66% | 31.59% | 38.37% |
| Income Tax Expenses | -23.08% | 4.76% | 68.16% | 144.82% | 206.82% |
| Earnings from Continuing Operations | -18.60% | -1.33% | 14.82% | 18.55% | 24.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.60% | -1.33% | 14.82% | 18.55% | 24.07% |
| EBIT | -15.48% | 3.66% | 20.03% | 25.03% | 31.91% |
| EBITDA | -14.71% | 4.49% | 21.32% | 26.23% | 33.24% |
| EPS Basic | -15.64% | 0.87% | 16.28% | 19.77% | 25.11% |
| Normalized Basic EPS | -27.50% | -1.67% | 19.59% | 26.19% | 29.69% |
| EPS Diluted | -15.65% | 0.86% | 16.28% | 19.76% | 25.11% |
| Normalized Diluted EPS | -27.50% | -1.67% | 19.59% | 26.19% | 29.69% |
| Average Basic Shares Outstanding | 2.80% | 2.30% | 1.73% | 1.40% | 1.52% |
| Average Diluted Shares Outstanding | 2.80% | 2.30% | 1.73% | 1.40% | 1.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |